Ultralife’s core business model is differentiated by its engineering and regulatory expertise in custom batteries for medical, industrial, and defense markets, supported by a record backlog and disciplined operational restructuring. The company’s technology is not radically unique, but its qualific…
Ultralife (ULBI) Q4 2025: Backlog Jumps 22% as New Products Drive $30M in Annual Sales
Ultralife ended 2025 with a record $110 million backlog, fueled by new product launches and a sharpened operational focus. Management’s consolidation of brands, facilities, and leadership signals a strategic pivot toward higher-margin growth and improved execution. With a diverse backlog and streamlined cost structure, the company is positioned for a rebound in its communications business and continued margin expansion in energy solutions.
Summary
- Backlog Expansion Sets Stage: Ultralife’s $110 million backlog, up 22%, signals improved demand visibility.
- Operational Restructuring Accelerates: Facility consolidation and unified branding aim to lift margins and efficiency.
- Growth Pipeline Broadens: New medical, industrial, and defense products underpin management’s organic growth ambitions.
Performance Analysis
Ultralife’s Q4 results reflected both underlying growth and the financial impact of restructuring. Total revenue climbed 10.6% year-over-year, driven by the battery and energy segment, which saw double-digit gains across medical and industrial verticals. Excluding the Electrochem, specialty battery acquisition, organic growth remained robust, with medical up nearly 40% and industrial up 20%.
Gross margin improvement was a highlight, as consolidated gross margin rose by 70 basis points to 24.9%, and the battery and energy segment’s margin expanded 170 basis points. However, a one-time $12.2 million non-cash intangible asset impairment related to brand consolidation drove a reported operating loss. Adjusted EBITDA margin improved to 11.7%, reflecting underlying operating leverage. The communications systems segment lagged, with revenue down 35%, but this was attributed to delayed government orders and is expected to rebound as programs restart in 2026.
- Backlog Diversification: The $110 million backlog covers commercial and defense customers, with $6 million from new 2025 product launches.
- Segment Mix Shift: Commercial sales now represent 66% of total revenue, up from 62% a year ago, highlighting reduced government dependency.
- Balance Sheet Stability: Working capital and liquidity remain solid, with acquisition debt repayments exceeding scheduled amortization.
Ultralife’s financials show a business in transition, with new product momentum and operational streamlining offsetting restructuring headwinds, while a healthy backlog provides visibility into 2026.
Executive Commentary
"During 2025, we completed the electric M transition and various operational initiatives to reduce ongoing costs. I am excited to see our backlog grow to $110 million exiting the year, diversified across several markets and applications with over 6 million of it driven from new products released in 2025."
Mike Manna, President and Chief Executive Officer
"Operating expenses were essentially flat year over year when excluding the $12.2 million non-cash intangible asset impairment charge as we transitioned from numerous sub-brands reflecting the names of our acquisitions to the Ultralife master brand."
Phil Fain, Chief Financial Officer
Strategic Positioning
1. Backlog and Demand Visibility
Ultralife’s year-end backlog of $110 million, representing 58% of trailing twelve-month sales, provides strong demand visibility into 2026. This backlog is diversified across commercial, industrial, medical, and defense customers, reducing concentration risk and supporting management’s organic growth targets.
2. New Product Commercialization
Over $30 million in 2025 revenue came from products launched within the last five years, with significant traction in medical wearables, industrial power packs, and defense systems. The pipeline includes thin-cell technology for medical sensors, a new amplifier for military communications, and a conformal wearable battery for soldier systems, all of which are expected to contribute meaningfully in 2026 and beyond.
3. Operational Streamlining and Brand Consolidation
Facility consolidation and the transition to a unified Ultralife master brand have reduced North American locations and eliminated redundant branding costs. The creation of the Telemetry Power Systems Division brings together U.S., Canadian, and Chinese operations under one leader, aiming to maximize synergies and accelerate gross margin improvement.
4. Margin Expansion Initiatives
External consultants and new leadership have been deployed to address yield and efficiency issues, particularly in the battery and energy business. Pricing revisions, cost-down projects, and vertical integration (leveraging Electrochem cell manufacturing) are expected to further support margin expansion in 2026.
5. Communications Systems Rebound
The communications segment, though down in Q4, is expected to recover as delayed government programs resume and new ruggedized computing products are fielded. Management targets a $25 million baseline revenue for this segment, with upside potential from large program wins.
Key Considerations
Ultralife’s 2025 results mark a strategic inflection, with management executing on restructuring, new product launches, and a push for operational efficiency. The balance between growth investments and cost discipline will be critical to sustaining momentum.
Key Considerations:
- New Product Pipeline Depth: Multiple medical, industrial, and defense products are moving from development to commercialization, but timing of customer certifications and order ramp remains a key execution variable.
- Margin Leverage Potential: Gross margin improvement initiatives are underway, but realization depends on successful operational fixes and vertical integration benefits.
- Communications Segment Recovery: The pace at which delayed government and military orders resume will impact overall revenue mix and profitability.
- Brand and Facility Rationalization: The shift to a unified brand and fewer locations should lower costs and reduce customer confusion, but execution risk remains as systems and teams are integrated.
Risks
Key risks include continued delays in government and defense procurement, which could slow the communications segment’s recovery. The timing of large medical and industrial orders is inherently uncertain, given long customer qualification cycles. Integration of recent acquisitions and execution of operational improvements carry risk, as does the potential for macroeconomic or supply chain disruptions. Management’s forward-looking statements are subject to these and other uncertainties disclosed in SEC filings.
Forward Outlook
For Q1 2026, Ultralife expects:
- Backlog conversion to drive higher revenue, with most of the $110 million backlog shipping in 2026
- Improved gross margin as operational initiatives take hold and product mix shifts toward higher-value solutions
For full-year 2026, management did not provide formal guidance but:
- Reiterated a target of organic growth at least two times GDP and an initial EBITDA margin goal above 10%
Management highlighted several factors that will influence results:
- Ramp of new medical and industrial programs
- Execution of facility and brand consolidation
Takeaways
Ultralife’s 2025 was a year of transition, with new products and backlog growth offsetting restructuring costs and communications segment softness.
- Backlog and Pipeline Strength: The $110 million backlog and robust new product pipeline provide a strong foundation for 2026 growth.
- Margin Expansion in Focus: Operational improvements and vertical integration should support higher gross margins if execution stays on track.
- Watch Communications Segment Rebound: The timing of government and defense order recovery will be a key swing factor for revenue mix and profit growth in upcoming quarters.
Conclusion
Ultralife’s fourth quarter and full-year results confirm a strategic pivot toward higher-margin, diversified growth. With operational streamlining largely complete and a record backlog, the company is poised to convert development wins into sustained revenue and margin expansion. The execution of new product ramps and communications segment recovery will determine the pace and durability of this inflection.
Industry Read-Through
Ultralife’s results underscore several broader industry trends: Demand for advanced battery and energy solutions is strong in medical, industrial, and defense markets, but order timing remains unpredictable due to long qualification cycles. The communications segment’s volatility highlights the impact of government procurement delays—a dynamic likely affecting peers with defense exposure. Facility consolidation, brand simplification, and vertical integration are becoming necessary levers for mid-cap industrials seeking to drive margin expansion and operational agility in a competitive landscape. Investors should monitor similar moves among specialty battery, electronics, and defense suppliers as sector tailwinds shift toward execution and efficiency.